Navigation Links
The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Date:8/14/2013

BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although currently not FDA-approved for treatment of ovarian cancer, is prescribed by approximately 70 percent of surveyed oncologists in first-line advanced ovarian cancer. Avastin is most frequently prescribed in first-line advanced ovarian cancer as an add-on agent to doublet platinum-based chemotherapy followed by continued administration of Avastin as a maintenance monotherapy. Approximately half of the surveyed oncologists who prescribe Avastin in first-line advanced ovarian cancer indicate that they encounter reimbursement barriers (such as prior authorization) when prescribing Avastin in this setting.

The U.S. Physician and Payer Forum report entitled Ovarian and Endometrial Cancer: How Will U.S. Prescriber and Payer Attitudes Toward Emerging Antiangiogenics and Other Targeted Anticancer Agents Shape the Treatment Landscape? finds that current treatment of ovarian and endometrial cancers relies heavily on generically available chemotherapies and that carboplatin/paclitaxel is very frequently prescribed in early-stage ovarian cancer, first-line advanced ovarian cancer and in early-stage and advanced endometrial cancer. However, the use of Avastin for treatment of ovarian cancer in all disease settings is common amongst surveyed oncologists and more than 65 percent of surveyed oncologists think that treatment rates with Avastin will increase in the next five years - primarily because they believe Avastin will gain regulatory approval for ovarian cancer. Avastin is rarely used by surveyed oncologists for treatment of endometrial cancer; however, surveyed oncologists believe that angiogenesis inhibitors can play a role in its treatment with 70 percent of surveyed oncologists responding that targeting the vascular endothelial growth factor (VEGF) pathway will likely be a promising treatment approach in this disease.

The report also finds that demonstrating a survival advantage over currently available therapies is of paramount importance to most surveyed managed care organizations' (MCOs) pharmacy directors (PDs) for formulary inclusion and favorable tier status for ovarian cancer therapies. Surveyed MCO PDs indicate that the cost of treatment has a smaller impact on these decisions.

"The high use of off-label Avastin in ovarian cancer means that novel therapies for ovarian cancer, such as Amgen/Takeda Pharmaceutical's trebananib, Merck/Endocyte's vintafolide and GlaxoSmithKline's Votrient (pazopanib), will not only face strong competition from generically available chemotherapies, but also from premium-priced Avastin," said Decision Resources Senior Business Insights Analyst Karen Pomeranz, Ph.D. "Strong efficacy data and competitive pricing of emerging therapies compared with Avastin will encourage a high proportion of surveyed MCO PDs to offer reimbursement to novel ovarian cancer therapies and physicians to incorporate these agents into the treatment algorithm."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Completes Sale of Majority of Discovery Labware Unit
2. Allscripts adopts majority voting policy for directors
3. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. Majority of Springfield Voters Oppose Prescription Only PSE Requirements
6. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
7. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and edit ... the reporting process and provides a familiar interface that does not require additional ...
(Date:4/28/2017)... ... , ... Getting enough sleep affects much more than energy – it also has mental and ... can compromise motor reaction time, which can increase the risk of having a car accident. ... tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... Cypress, California (PRWEB) , ... April 28, 2017 ... ... LED T8 Direct Replace tubes . These lamps offer an instant energy-saving solution ... no need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... ... 28, 2017 , ... Early detection and elimination of new ... minimize the cost of development. In this webinar, sponsored by Molecular Devices, an ... for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In the first ...
Breaking Medicine News(10 mins):